MX379649B - Derivados de azetidina para formacion de imágenes de tau. - Google Patents

Derivados de azetidina para formacion de imágenes de tau.

Info

Publication number
MX379649B
MX379649B MX2018005376A MX2018005376A MX379649B MX 379649 B MX379649 B MX 379649B MX 2018005376 A MX2018005376 A MX 2018005376A MX 2018005376 A MX2018005376 A MX 2018005376A MX 379649 B MX379649 B MX 379649B
Authority
MX
Mexico
Prior art keywords
tau imaging
azetidine derivatives
tau
imaging
compound
Prior art date
Application number
MX2018005376A
Other languages
English (en)
Other versions
MX2018005376A (es
Inventor
Carey Horchler
Giorgio Attardo
Hui Xiong
Shyamali Ghosh
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2018005376A publication Critical patent/MX2018005376A/es
Publication of MX379649B publication Critical patent/MX379649B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0444—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un nuevo compuesto de la fórmula: métodos de preparación de este compuesto, métodos de uso de este compuesto para imágenes tau y preparaciones de formulaciones de formación de imágenes de tau.
MX2018005376A 2015-11-13 2016-11-04 Derivados de azetidina para formacion de imágenes de tau. MX379649B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562254906P 2015-11-13 2015-11-13
PCT/US2016/060621 WO2017083198A1 (en) 2015-11-13 2016-11-04 Azetidine derivatives for tau imaging

Publications (2)

Publication Number Publication Date
MX2018005376A MX2018005376A (es) 2018-08-01
MX379649B true MX379649B (es) 2025-03-11

Family

ID=57389526

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005376A MX379649B (es) 2015-11-13 2016-11-04 Derivados de azetidina para formacion de imágenes de tau.

Country Status (18)

Country Link
US (1) US10301308B2 (es)
EP (1) EP3374358B1 (es)
JP (1) JP2018531978A (es)
KR (1) KR20180061364A (es)
CN (1) CN108290883B (es)
AU (1) AU2016351609B2 (es)
BR (1) BR112018006969B1 (es)
CA (1) CA3003884C (es)
DK (1) DK3374358T3 (es)
EA (1) EA034018B1 (es)
ES (1) ES2864825T3 (es)
IL (1) IL258313B (es)
MX (1) MX379649B (es)
PL (1) PL3374358T3 (es)
PT (1) PT3374358T (es)
SA (1) SA518391527B1 (es)
WO (1) WO2017083198A1 (es)
ZA (1) ZA201802526B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314657A (en) * 2022-02-03 2024-09-01 Lilly Co Eli Regional tau imaging for diagnosing and treating alzheimer's disease
JP2026504445A (ja) * 2023-02-02 2026-02-05 イーライ リリー アンド カンパニー タウイメージングのための新規化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054978A1 (ja) * 2002-12-16 2004-07-01 Bf Research Institute, Inc. タウ蛋白蓄積性疾患の診断プローブとしてのキノリン誘導体
WO2009102498A1 (en) 2008-02-14 2009-08-20 Siemens Medical Solutions Usa, Inc. Novel imaging agents for detecting neurological dysfunction
CN102271716B (zh) * 2008-12-31 2014-11-19 阿维德放射性药品公司 由甲苯磺酸酯前体合成18f-放射性标记的苯乙烯基吡啶及其稳定的药物组合物
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CA2873963C (en) 2012-05-22 2017-04-11 Eli Lilly And Company Carboline and carbazole based imaging agents for detecting neurological dysfunction

Also Published As

Publication number Publication date
CN108290883A (zh) 2018-07-17
HK1257042A1 (zh) 2019-10-11
CA3003884C (en) 2020-04-21
US10301308B2 (en) 2019-05-28
AU2016351609A1 (en) 2018-04-19
EP3374358A1 (en) 2018-09-19
AU2016351609B2 (en) 2019-08-08
SA518391527B1 (ar) 2021-02-07
KR20180061364A (ko) 2018-06-07
CN108290883B (zh) 2021-02-09
IL258313A (en) 2018-05-31
DK3374358T3 (da) 2021-03-08
BR112018006969A2 (en) 2018-10-16
MX2018005376A (es) 2018-08-01
CA3003884A1 (en) 2017-05-18
PL3374358T3 (pl) 2021-07-12
BR112018006969B1 (pt) 2022-04-26
ES2864825T3 (es) 2021-10-14
PT3374358T (pt) 2021-03-31
EA201890799A1 (ru) 2018-10-31
EA034018B1 (ru) 2019-12-19
IL258313B (en) 2021-04-29
EP3374358B1 (en) 2021-02-17
WO2017083198A1 (en) 2017-05-18
JP2018531978A (ja) 2018-11-01
US20180282322A1 (en) 2018-10-04
ZA201802526B (en) 2019-10-30

Similar Documents

Publication Publication Date Title
AR132627A2 (es) Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
PH12018500457A1 (en) New phenoxymethyl derivatives
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EP4279071A3 (en) Novel cannabinoid formulations
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
CY1121746T1 (el) Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201790570A1 (ru) Модуляторы р2х7
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201790275A1 (ru) Кристаллические формы 6-((6,7-диметоксихиназолин-4-ил)окси)-n,2-диметилбензофуран-3-карбоксамида
EA201792262A1 (ru) Пироглутамат вортиоксетина
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
EP3682016A4 (en) FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
MX2016015298A (es) Inhibidores de nampt y metodos.